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CYTOKINE PROFILE IN MONTENEGRO SKIN TEST OF PATIENTS WITH LOCALIZED CUTANEOUS 
AND MUCOCUTANEOUS LEISHMANIASIS
Marcia Ferraz Nogueira(1), Hiro goto(2), Mírian Nacagami Sotto(3) & Luiz Carlos CuCé(4)
SuMMarY
American tegumentary leishmaniasis presents as two major clinical forms: localized cutaneous leishmaniasis (LCL) and 
mucocutaneous leishmaniasis (MCL). The immune response in leishmaniasis is efficiently evaluated by the response to Leishmania 
antigen through the Montenegro skin test (MST). Both LCL and MCL present positive response to MST, indicating that the patients 
present cell-mediated immunity against the parasite - Leishmania. In spite of the presence of immunity in MCL, this is not sufficient to 
stop disease progression and prevent resistance to treatment. In this study we demonstrated interleukin (IL) 2, 4, 5 and interferon (IFN) 
gamma expression in biopsies of MST of ten patients with American tegumentary leishmaniasis. The obtained results were compared 
between LCL (n = 5) and MCL (n = 5) patients. The MST of MCL patients displayed a higher expression of IL-2, IL-4 and IL-5, in 
comparison to LCL. There was no significant difference in IFN-gamma expression between groups. The obtained results suggest the 
role of IL-4 and IL-5 in the maintenance of the immunopathogenic mechanism of the destructive lesions that characterize MCL.
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iNtroDuCtioN
Leishmaniasis is a disease caused by protozoa of the genus 
Leishmania, which can occur as the tegumentary or visceral form. It is 
an endemic anthropozoonosis found in 88 countries around the world, 
with an estimated 12 million cases worldwide and 1.5 to 2 million new 
cases occurring annually, 1 to 1.5 million cases are of tegumentary 
leishmaniasis and 500,000 cases of visceral leishmaniasis33. In Brazil, 
around 30,000 tegumentary leishmaniasis cases are reported annually3, 
the majority of them caused by Leishmania (Viannia) braziliensis31.
Clinical manifestations of tegumentary leishmaniasis are diverse, but 
the most frequent forms in Brazil are localized cutaneous leishmaniasis 
(LCL) and mucocutaneous leishmaniasis (MCL). LCL is characterized 
by the presence of a single or few ulcers, usually present in exposed areas 
of the body, usually healing after therapy. MCL is characterized by the 
presence of infiltrated lesions in the oral, nasal, pharyngeal and laryngeal 
mucosa membranes and skin of the surrounding areas. It usually manifests 
months or years after healing of the localized cutaneous lesion. These 
lesions are usually resistant to therapy, often disfiguring the face17. 
The evolution of the disease depends on the species of the protozoa and 
the host’s immune response10,28. In human and experimental leishmaniasis, 
immunity is predominantly mediated by lymphocytes. In experimental 
cutaneous leishmaniasis, using isogenic mouse strains infected with 
Leishmania (Leishmania) major, a paradigm was established associating a 
subpopulation of CD4+ T cells producing mainly IFN-gamma (T helper 1 
cells = Th1 cells) to the resistance, and CD4+ T cells producing mainly IL-4 
and IL-10 (T helper 2 cells = Th2 cells) to susceptibility18,27. However, in the 
patients with LCL and MCL, the pathogenesis does not seem to be related 
only to the difference in the host’s susceptibility, as not many parasites are 
seen in the lesions, even in the most severe mucocutaneous form of the 
disease. This condition differs from what is observed in the lesions of the 
susceptible mouse, with diffuse cutaneous leishmaniasis, where there is 
a high expression of IL-4 and lots of parasites. Furthermore, the delayed-
type hypersensitivity reaction to MST, counterpart of the T-cell mediated 
immunity, is positive in both forms of the disease. Indeed, in MCL this 
immune response does not prevent the aggressive evolution of the disease28. 
Differently, in this context, cytokines may play different roles in the 
pathogenesis, being more related to the maintenance of the inflammatory 
reaction in the tissue. Studies in this context have identified both Th1 and 
Th2-type cytokines in Leishmania antigen-stimulated peripheral blood 
mononuclear cell supernatant in LCL11,13,15 and also in MCL13. PCR studies 
of lesion samples have shown Th1 profile LCL and both Th1 and Th2 in 
MCL26. On the other hand, immunohistochemistry analysis demonstrated 
both Th1 and Th2 -cytokine expression in LCL lesions14. These apparently 
controversial observations might be due to the different assays used and 
to the comparison of peripheral blood mononuclear cells and in situ 
inflammatory cell results. 
A positive MST is an indication of the presence of cell-mediated 
immune response of the host against Leishmania. In the present study, we 
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demonstrated the expression of IFN-gamma, interleukin (IL) 2, 4 and 5, in 
MST biopsies of LCL and MCL in order to address the immunopathogenic 
mechanism in these different forms of leishmaniasis. 
MateriaL aND MetHoD
The sample study consisted of ten patients (eight males and two 
females) aged 19 to 82 years (mean age of 49.5 years), with confirmed 
diagnosis of American tegumentary leishmaniasis. The five LCL and 
five MCL patients had just started the specific treatment for the disease. 
The study was approved by the Ethics Research Board of the Institutions 
(University of São Paulo and Santo Amaro Medical School). Informed 
consent was obtained from all patients. Nine patients were from different 
regions of Brazil and one patient was from Bolivia (patient 3). The mean 
± standard deviation (SD) time of disease was 8 ± 6.2 months in LCL 
and 20.1 ± 19.9 years in MCL. 
The diagnosis of leishmaniasis was confirmed by: the direct 
parasitological test, histopathological assessment including the 
demonstration of Leishmania antigen by immunohistochemistry in the 
lesions32, positive MST, and detection of anti-Leishmania antibody in the 
serum (by indirect immunofluorescence technique and ELISA).
Montenegro skin test: A sample of 100 mL of dead Leishmania 
promastigote suspension, in phenolic and sodium fluoride solution (two 
to three millions microorganisms per mL, called Montenegro antigen, 
produced at Adolfo Lutz Institute, in São Paulo, Brazil) was injected 
intradermally in the arm of each patient21. 
MST biopsies were obtained before specific treatment in eight 
patients, and 15 and 18 months after treatment in two patients with 
LCL.
The MST evaluation was carried out 72 hours after antigen 
inoculation, by measuring two diameters of the resulting papule. The 
mean of the two diameters was calculated for statistical analysis. MST 
with papule = 5 mm, was considered positive4. 
The biopsy samples were taken from the center of the erythematous 
papule using a 4-mm punch, under local anesthesia with 2% xylocaine, 
after the MST clinical evaluation. The control skin sample of the assessed 
cases consisted of normal skin biopsies from the contralateral arm.
Detection of cytokines in the skin by immunohistochemical 
technique: Skin fragments were placed in sterile saline solution, later 
pre-frozen in isopentane and finally frozen in liquid nitrogen at -180 ºC. 
Fragments were kept at -80 ºC and later sectioned in cryostat.
Cytokines were detected by the immunohistochemical method, using 
anti-human IL-2, anti-human IL-4, anti-human IL-5 and anti-human IFN-
gamma purified monoclonal goat IgG, purchased from R&D Systems 
(MN, USA). Four-µm cryostat sections were immersed in acetone for 10 
minutes, dried at room temperature, followed by immersion in water for 
five minutes. After serial incubation to prevent nonspecific staining with 
0.03% hydrogen peroxide in Tris solution, pH 7.4, and afterward with 
bovine serum albumin for one hour at 37 ºC, the sections were incubated 
with the primary antibody for 12 hours at 8 ºC. That was followed by 
incubation with goat biotinylated antibody IgG (R&D Systems, MN, USA) 
and with peroxidase-conjugated avidin for 30 minutes at 37 ºC. The slides 
were washed with 0.01 M phosphate-buffered saline, pH 7.2 (PBS) after 
each incubation step. The reaction was developed using 0.06% hydrogen 
peroxide and 0.3 mg/mL 3,3'-diaminobenzidine (Sigma Chemical, USA) 
in PBS. Counterstaining was performed with Harry's hematoxylin (Sigma 
Chemical, USA). The cytokines were identified in a light brown color.
Semi quantification of the cytokine staining: Immunostaining of 
the cytokines in the dermis was analyzed and semi-quantified by two 
independent investigators, by attributing scores as follows: zero for 
negative immunolabeling; 1+ for up to one third of positive stained 
mononuclear cells in the dermal cell infiltrate; 2+ for more than one 
third up to two thirds of positive stained mononuclear cells in the dermal 
infiltrate; 3+ for more than two thirds of positive stained mononuclear 
cells in the dermal infiltrate. In case of discordance between the two 
independent investigators, an independent third investigator provided 
consensus about the final score.
Statistical analysis: We analyzed the arithmetic mean and median 
of the results from the two groups of patients and analyzed them by 
Friedman’s and Fisher’s tests. The level of significance was set at 0.05.
reSuLtS
Intensity of the Montenegro skin test: The results of the MST in 
LCL and MCL are shown in Table 1. 
The mean value of the MST intensity, evaluated at the time of the 
patients’ diagnoses, was significantly higher in the MCL when compared 
to the LCL group (p < 0.01). On the other hand, there was no significant 
difference regarding the MST evaluation when the groups were tested 
again before the biopsy procedure. In addition, we did not find any 
statistical difference between the intensity of the MST, at the diagnostic 
procedures as well as at the time of the study, in both LCL and MCL 
patients. 
Detection of cytokines in Montenegro skin test: The median values 
of the cytokines in LCL and MCL are shown in Table 2. 
table 1
Intensity of the Montenegro skin test, obtained from the two papule diameters 
(mm), in both studied groups, localized cutaneous leishmaniasis (LCL) and 
mucocutaneous leishmaniasis (MCL) at the time of diagnoses and at the time 
of the present study
Groups 
n = number  
of cases
At diagnoses Present study
LCL (n = 5) Mean ± Sd* 
Range 
Median
9.9 ± 3.7  
7 - 15  
8
10.2 ± 4.7  
6 - 18  
10
MCL (n = 5) Mean ± Sd* 
Range 
Median
21.7 ± 14.7  
10 - 45  
14
13.3 ± 3.0   
10 - 17.5  
14
†p < 0.01 No significance
*Sd: Standard deviation; † Fisher test
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There was a predominance of Th1 cytokine profile in the Montenegro 
skin tests in LCL. The statistical analyses showed a predominance of 
IFN-g in comparison to the other three cytokines (p < 0.05). 
Both types of cytokine profiles (Th1 and Th2) were observed in 
MCL patients. 
No cytokine expression was observed in the normal control skin of 
all patients studied. 
The statistical analyses showed a higher expression of IL-2, IL-4 
and IL-5 in the dermal infiltrate of MCL when compared with LCL 
patients (p < 0.01).
DiSCuSSioN
The immune response in cutaneous leishmaniasis is characterized by 
a cell-mediated immune response, with a wide participation of humoral 
immunity6. The cellular immune response in leishmaniasis is clinically 
evidenced by Montenegro skin test23,28. 
In this study, the results of the intensity of the MST were different 
at the diagnosis and at the time of the present study, showing that the 
MST can change clinically with a second inoculation, as it has been 
demonstrated by other investigators1,24. In spite of that, the MST remains 
positive before and after treatment, and therefore, the MST response 
is independent from the treatment8, although we cannot be certain 
about the changes of the MST intensity after treatment, as this has not 
been measured by the authors. In comparison with in vitro studies, the 
treatment does not change the immunological response of the patients 
with LCL, as demonstrated by some authors1,13,30. DA-CRUZ et al.13 
demonstrated in peripheral blood of patients with localized cutaneous 
leishmaniasis caused by L. braziliensis, that the type of cytokine remains 
the same, i.e., the Th1 type, before and after the treatment. This fact 
supports our findings in the MST that was performed after treatment in 
two patients of LCL. However, in MCL patients, a change in cytokine 
profile after treatment has been observed in vitro, as the observed Th1 
and Th2 types, changed to Th1 type11,13.
The population of T lymphocytes present in the granulomatous 
infiltrate of the lesion of tegumentary leishmaniasis was mainly composed 
by CD4+ cells, and a lower proportion of CD8+ cells6,9,22,25. The subtypes 
of CD4+ T cells (Th1 and Th2 profile) have been characterized by many 
investigators in all forms of tegumentary leishmaniasis. 
The immune response of the New World LCL caused by L. 
braziliensis, is characterized by a Th1 response, with a predominance of 
IFN-gamma expression in vitro and in situ and a very low or sometimes 
absent expression of IL-4, IL-5 and IL-101,2,5,11-15,20. In relation to other 
cytokines, such as IL-2, they have been demonstrated in vitro and in 
situ, with a low expression. Additionally, the immune response of the 
Old World LCL caused by L. major, L. tropica and L. aethiopica, is 
characterized by this same cytokine profile (Th1), also observed by many 
investigators19,29. However, in acute and chronic lesions of LCL, studied 
in situ and with stimulation of peripheral blood mononuclear cells by 
Leishmania antigen, the cytokines in acute lesions show a tendency to 
the Th1 type, whereas, in chronic lesions, there is a tendency to a mixed 
cytokine type19,29.
MCL is characterized by a mixture of Th1 and Th2 responses, which 
has been well established by two investigators using different techniques, 
both in situ and in vitro26. The cytokines observed in MCL are IL-4, IL-5, 
IL-10 at a higher proportion in comparison to LCL11,13,14, but lower than 
in diffuse cutaneous leishmaniasis4,22.
The Th1 response in MCL is more intense than in LCL, as 
demonstrated by the IFN-gamma and IL-2 that are observed at high 
proportions in vitro and in situ, and an exacerbated lymphoproliferative 
response to Leishmania antigen in vitro4,6,31. 
In the present study, we demonstrated a difference in the cytokine 
profile identified in the MST of patients with LCL and MCL. There 
was a predominance of Th1 response in the MST of LCL patients and 
both types, Th1 and Th2, in the MST of MCL patients. We observed 
a significantly higher expression of IL-2 (p < 0.05), IL-4 and IL-5 in 
MCL in comparison to LCL (p < 0.01). Initially, we thought that a low 
expression of IL-2 in the LCL group was due to a technical problem, 
table 2
 Detection of cytokines by immunoperoxidase technique, in the Montenegro skin test of localized cutaneous leishmaniasis (LCL)  
and mucocutaneous leishmaniasis (MCL)
Groups IFN-g IL-2 IL-4 IL-5 Within subjects  
effects *
LCL
Mean ± Sd* 2.2 ± 0.8 1 ± 1 0.6 ± 0.9 0.6 ± 0.5
*p < 0.05Range 1 - 3 0 - 2 0 - 2 0 - 1
Median 2* 1 0 1 
MCL
Mean ± Sd* 2.8 ± 0.4 2.4 ± 0.9 3 ± 0 3 ± 0
No significanceRange 2 - 3 1 - 3 0 0
Median 3 3 * 3 ** 3 **
Between groups 
effects** No significance *p < 0.05 **p < 0.01 **p < 0.01
*,** Friedman test; Sd: Standard deviation.
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but the literature shows how weakly this cytokine is expressed in this 
group; its expression is a little higher in MCL, although at a very low 
frequency. Perhaps this cytokine is important for the initiation of the 
immune response, but not for its maintenance. Finally, the results showed 
no difference in IFN-gamma expression in both groups studied.
The predominance of IL-4 and IL-5 in Montenegro skin test of MCL 
may suggest that these cytokines participate in the modulation of the 
inflammatory reaction caused by the high amount of IFN-gamma. The 
destructive lesions may occur when the high quantities of IFN-gamma 
are not controlled by the Th2 cytokines7.
In this study, the identification of the immunological aspects 
demonstrated in the MST is similar to those seen in ATL lesions. We 
suggest that the MST can be used as a mirror of the disease itself. These 
aspects have also been demonstrated by other authors in studies about the 
inflammatory response in the MST16,22,26. On the other hand, these studies 
did not compare the in situ MST immunopathological characteristics 
in the two forms of the disease. Further studies are needed to compare 
the expression of cytokines in leishmaniotic lesions and MST biopsies 
simultaneously. Perhaps, we will be able to study the immune response 
of these two clinical forms during a phase of the disease when there are 
no lesions, but only the positive response of the MST. This reaction has 
83.7 to 100% of sensitivity, it is very specific for the Leishmania genus 
and it stays positive for a long time after the cure or even throughout 
life17,23,28. We must remember that the blood lymphocytes represent 5% 
of all lymphocytes and that these cells stay in circulation for only one 
hour, so the study using these techniques sometimes do not actually show 
the reality of the disease. 
The Montenegro skin test may show earlier changes, before the 
symptoms appear in the mucosa of the patients, so it is the only test able 
to assess the patient’s immunological reaction to the Leishmania antigen, 
before the mucocutaneous form appears. The MST might be able to 
answer a question that is so often formulated: When does the localized 
form change to the mucocutaneous form?
reSuMo
Perfil de citocinas na intradermorreação de Montenegro em 
doentes de leishmaniose cutânea localizada e cutâneo-mucosa
A leishmaniose tegumentar americana apresenta duas formas clínicas 
mais comuns: a leishmaniose cutânea localizada e a leishmaniose 
cutâneo-mucosa. A imunidade da leishmaniose é avaliada pela resposta 
ao antígeno Leishmania através da Intradermorreação de Montenegro. 
Estas duas formas apresentam resposta positiva, indicando que o paciente 
apresenta imunidade celular contra o parasita Leishmania. Apesar da 
presença da imunidade celular na leishmaniose cutâneo-mucosa, esta não é 
suficiente para barrar a progressão da doença e a resistência ao tratamento. 
Neste estudo, detectamos quatro citocinas por imunohistoquímica, IL-2, 
IL-4, IL-5 e IFN-gama nas biópsias da intradermorreação de Montenegro 
de pacientes com leishmaniose tegumentar americana (n = 10), cinco 
com leishmaniose cutânea e cinco com cutâneo-mucosa. Os resultados 
mostraram uma alta expressão significativa de IL-2, IL-4, IL-5 na 
leishmaniose cutâneo-mucosa comparada com a leishmaniose cutânea 
localizada, mas sem diferença significante na expressão do IFN-g entre 
os grupos. Estes resultados sugerem a importância da participação da 
citocina IL-4 e IL-5 na manutenção do mecanismo imunopatogênico das 
lesões destrutivas da forma cutâneo-mucosa.  
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